Back to top

immuno-therapy: Archive

Zacks Equity Research

IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK

ImmunityBio stock rises 27% on completing the regulatory filing process in the EU and the U.K. for the Anktiva/BCG combo to treat NMIBC CIS patients.

BMRNNegative Net Change CTMXNegative Net Change CSTLNegative Net Change IBRXNo Net Change

Ekta Bagri

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.

ALNYNegative Net Change EXELNegative Net Change SRPTNegative Net Change ADMANegative Net Change

Zacks Equity Research

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Krystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy candidate, KB707.

CTMXNegative Net Change SPRONegative Net Change KRYSNegative Net Change CSTLNegative Net Change

Zacks Equity Research

ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline

AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.

ABBVNegative Net Change CTMXNegative Net Change SPRONegative Net Change CSTLNegative Net Change

Zacks Equity Research

EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease

The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.

JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change

Zacks Equity Research

CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal

Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer.

BMYNegative Net Change PFENegative Net Change GILDPositive Net Change CADLNegative Net Change